OTLK Outlook Therapeutics Inc.

1.58
-0.01  -1%
Previous Close 1.59
Open 1.62
Price To Book -0.7
Market Cap 18584750
Shares 11,762,500
Volume 758,756
Short Ratio
Av. Daily Volume 289,653

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial 75% enrolled as of February 14, 2019.
ONS-5010
Wet age-related macular degeneration (wet AMD)
Phase 3 trial to be initiated 2Q 2019.
ONS-5010-002
Wet age-related macular degeneration (wet AMD)